Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00911586 · ClinicalTrials.gov registry record · Phase 2
Pharmacokinetic Study to Determine Time to Steady-state
A Phase 2 study of Secondary Hypogonadism and Male Hypogonadism, sponsored by Clarus Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00911586 is a Phase 2 study of Secondary Hypogonadism and Male Hypogonadism that has completed, run by Clarus Therapeutics. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00911586, a Phase 2 study of Secondary Hypogonadism and Male Hypogonadism, has completed, sponsored by Clarus Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
Conditions Studied
Interventions
- DRUG Testosterone undecanoate
Study Locations (1)
Alabama
- Alabama Clinical Therapeutics - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00911586
The ClinicalTrials.gov registry entry for NCT00911586 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clarus Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Secondary Hypogonadism appearing as the primary indexed condition, and to 1 intervention - of which Testosterone undecanoate is the first listed.
NCT00911586 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT00911586 about?
NCT00911586 is a clinical study titled "Pharmacokinetic Study to Determine Time to Steady-state". The purpose of the study is to confirm how long (i.e., how many days) it takes to reach steady-state when testosterone undecanoate is administered twice daily.
What is the current status of trial NCT00911586?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2009-07. Estimated completion is 2010-01.
What conditions does trial NCT00911586 study?
This clinical trial studies the following conditions: Secondary Hypogonadism, Male Hypogonadism, Primary Hypogonadism.
What interventions are being tested in trial NCT00911586?
The interventions under investigation include: Testosterone undecanoate (DRUG).
Who is sponsoring clinical trial NCT00911586?
This trial is sponsored by Clarus Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00911586 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Secondary Hypogonadism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.